Global Rozanolixizumab Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Rozanolixizumab Market was valued at $550 mn. in 2025. During the forecast period 2025-2030, it is expected to grow at 18.5% CAGR, to an estimated market size of $1.3 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The market encompasses the global commercialization and therapeutic use of Rozanolixizumab (brand name Rystiggo), a humanized monoclonal antibody and neonatal Fc receptor (FcRn) antagonist. The scope primarily includes its application for generalized myasthenia gravis (gMG) in adults who are anti-AChR or anti-MuSK antibody-positive, while excluding non-specific immunosuppressive therapies and other non-FcRn targeted biologics.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Rozanolixizumab Market in the period 2025-30:
- The therapeutic paradigm is shifting from broad immunosuppression to targeted FcRn inhibition, which selectively reduces pathogenic IgG antibodies without global immune depletion.
- The subcutaneous administration of Rozanolixizumab offers a significant competitive advantage in patient convenience and reduced treatment burden compared to intravenous alternatives.
- Market growth is heavily driven by the drug's unique approval for both anti-AChR and anti-MuSK antibody-positive gMG patients, addressing a previously underserved segment.
- Ongoing clinical trials for additional indications such as Immune Thrombocytopenia (ITP) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) are expected to expand the addressable patient population by 2030.
- High treatment costs and complex reimbursement pathways remain the primary barriers to adoption in emerging markets and price-sensitive regions.
- Increasing diagnostic accuracy and rising prevalence of autoimmune disorders are expanding the pool of eligible patients for advanced biologic therapies.
- The competitive landscape is intensifying as FcRn blockers like Efgartigimod compete for market share, forcing a focus on clinical differentiation and patient access programs.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Generalized Myasthenia Gravis (gMG)
- Other Indications (ITP, CIDP, MOGAD)